Boehringer Mannheim/Ontogeny $40 mil. R&D agreement focuses on bone disorder research.
Executive Summary
BOEHRINGER MANNHEIM/ONTOGENY $40 MIL. BONE DISORDER R&D AGREEMENT will involve application of Cambridge, Mass.-based Ontogeny's "hedgehog" molecule research to treatment of bone, cartilage and other skeletal disorders. Ontogeny will receive milestone payments, and Boehringer Mannheim will acquire a less than 5% equity stake in Ontogeny as part of the five-year program.